Parthenon Therapeutics Raises $65 Million In Series A Funding To Advance Oncology Programs Aimed At Reprogramming The Tumor Microenvironment
Nov 03, 2021•over 3 years ago
Amount Raised
$65 Million
Round Type
series a
Description
Parthenon Therapeutics, a biotech company inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment, today announced a $65 million Series A financing led by Northpond Ventures, Pfizer Ventures, and Taiho Ventures. Additional investors included Section 32, Breakout Ventures, funds managed by Tekla Capital Management LLC, Creacion Ventures, KdT Ventures, Park West Asset Management LLC, and Alexandria Venture Investments. The company plans to use the funds to develop new therapies that target immune exclusion in tumors.
Funding Insights
Based on industry dataTech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech